Study warns against global use of old asthma medicines for kids' coughs

July 19, 2005

An asthma medicine widely used around the world to stop children's coughs has no provable benefit for that purpose and may cause harm, a new review of existing studies reports.

The class of drugs known as methylxanthines is no longer used to treat childhood asthma in Western countries, having been replaced by corticosteroids. But the drugs remain the leading therapy for asthma in the developing world, where they are also used to cure routine coughing in children.

"We found a lack of good evidence for using methylxanthines for children's cough that was not associated with other asthma symptoms," says lead study author Anne Chang, M.D., at Royal Children's Hospital in Queensland, Australia.

These medications are known by brand names Accubron Syrup, Aquaphyllin Syrup, Asmalix Elixir, Lanophyllin Elixir, Slo-Phyllin Syrup, Theoclear-80 Syrup, and Theolair Solution.

"This drug was widely abandoned in the U.S. when safer alternatives became available for the immediate relief of wheezing," says Richard L. Gorman, M.D., chair of the American Academy of Pediatrics Committee on Drugs.

The review appears in the July issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

Methylxanthines work in part by relaxing the bronchial airways, which helps to reduce coughing, wheezing, shortness of breath or difficulty breathing. They are also potentially dangerous for children, impairing the developing nervous system, and causing irritability, seizures and cardiac arrhythmias that lead to death.

Chang and colleagues searched the published literature for studies that analyzed methylxanthines' effectiveness for children suffering from coughing not related to disorders like cystic fibrosis or asthma. They found four studies, but they were of a limited design, not solid enough to suggest methylxanthine should be used for garden-variety kids' coughs, according to the study.

"The Cochrane Review states there is no data to support the use of methylxanthines. I would strongly concur," Gorman says.

Given the challenges chronic coughing poses for children, Chang and colleagues say methylxanthines should be considered as a potential treatment, but only after more research and only with careful awareness of its side effects.

"Knowledge is always desirable," Gorman notes. "While methylxanthines would not be my first choice of agents to study, a well designed trial or series of trials that demonstrated efficacy in certain situations or lack of efficacy in the face of well known toxicities would be very welcome."

"Information that could be used to stop unsafe practices is as important as information that can be used for effective new therapies," Gorman says.
-end-
FOR MORE INFORMATION
Health Behavior News Service: (202) 387-2829 or www.hbns.org.
Interviews: Contact Anne Change, tel. +61 736369149, email annechang@ausdoctors.net

To receive a full copy of the review, contact Julia Lampam at +44 (0) 1243 770668 or jlampam@wiley.co.uk

Chang AB, Halstead RA, Petsky HL. Methylxanthines for Prolonged Non-specific Cough in Children. (Review) The Cochrane Database of Systematic Reviews 2005, Issue 3

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit http://www.cochrane.org for more information.

Center for Advancing Health

Related Asthma Articles from Brightsurf:

Breastfeeding and risks of allergies and asthma
In an Acta Paediatrica study, exclusive breastfeeding for the first 3 months was linked with a lower risk of respiratory allergies and asthma when children reached 6 years of age.

Researchers make asthma breakthrough
Researchers from Trinity College Dublin have made a breakthrough that may eventually lead to improved therapeutic options for people living with asthma.

Physics vs. asthma
A research team from the MIPT Center for Molecular Mechanisms of Aging and Age-Related Diseases has collaborated with colleagues from the U.S., Canada, France, and Germany to determine the spatial structure of the CysLT1 receptor.

New knowledge on the development of asthma
Researchers at Karolinska Institutet in Sweden have studied which genes are expressed in overactive immune cells in mice with asthma-like inflammation of the airways.

Eating fish may help prevent asthma
A scientist from James Cook University in Australia says an innovative study has revealed new evidence that eating fish can help prevent asthma.

Academic performance of urban children with asthma worse than peers without asthma
A new study published in Annals of Allergy, Asthma and Immunology shows urban children with poorly controlled asthma, particularly those who are ethnic minorities, also suffer academically.

Asthma Controller Step Down Yardstick -- treatment guidance for when asthma improves
The focus for asthma treatment is often stepping up treatment, but clinicians need to know how to step down therapy when symptoms improve.

Asthma management tools improve asthma control and reduce hospital visits
A set of comprehensive asthma management tools helps decrease asthma-related visits to the emergency department, urgent care or hospital and improves patients' asthma control.

Asthma linked to infertility but not among women taking regular asthma preventers
Women with asthma who only use short-acting asthma relievers take longer to become pregnant than other women, according to research published in the European Respiratory Journal.

What are the best ways to diagnose and manage asthma?
A team of experts from The University of Texas Medical Branch at Galveston examined the current information available from many different sources on diagnosing and managing mild to moderate asthma in adults and summarized them.

Read More: Asthma News and Asthma Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.